Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04090697
Other study ID # Oxandrolone
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date December 20, 2019
Est. completion date September 19, 2023

Study information

Verified date July 2023
Source Carelon Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary aim of this study is to determine if clinically relevant doses of buccally administered oxandrolone are safe and tolerable in neonates with hypoplastic left heart syndrome (HLHS) or other single right ventricular anomalies who have undergone a Norwood procedure. The secondary aim is to evaluate the efficacy of buccally administered oxandrolone in improving objective indices of growth and nutrition in neonates who have undergone a Norwood procedure.


Description:

The proposed investigation is a Phase I/II randomized trial of 28 days of open label oxandrolone vs. no oxandrolone treatment to assess optimal dosing, safety/tolerability, and preliminary efficacy of this therapy in post-Norwood neonates with HLHS. Control subjects will receive standard therapy with no placebo and no oxandrolone. This trial is aimed at cumulative dose finding as well as a preliminary assessment of safety/tolerability and efficacy. The design and dosing are based upon preliminary phase I data obtained as part of an ongoing protocol under IND #107706. This trial will initially include two arms (control and 0.1 mg/kg oxandrolone BID). This initial oxandrolone dose was chosen based on the preliminary data collected in the background studies conducted for this trial. There were no adverse safety outcomes in the small cohort of subjects receiving 0.1 mg/kg of oxandrolone BID. In Cohort 1, subjects will be block randomized into each arm in a 1:4 (control to oxandrolone) ratio. An interim analysis of the safety data will be performed after the first 25 subjects in Cohort 1 have been randomized and have completed 28 days of oxandrolone therapy or observation (control group). If there are no significant differences in the primary safely/tolerability outcome and safety reviews are favorable for BID dosing, then Cohort 2 (25 subjects) will be randomized in a 1:4 ratio to the control and TID dosing arms. A similar interim analysis will be performed after Cohort 2 subjects have been randomized and completed 28 days of oxandrolone therapy. Enrollment will again be suspended during this second interim analysis to determine if dose escalation is warranted. Cohort 3A, utilizing 0.15 mg/kg oxandrolone TID would be possible if both Cohorts 1 (0.1 mg/kg BID) and 2 (0.1 mg/kg/dose TID) do not demonstrate any differences in the primary safety/tolerability outcome compared to controls and safety reviews are favorable (Figure 4). If the safety threshold is crossed, then a dose of 0.1 mg/kg/dose BID will be used for cohort 3B. An interim safety analysis will be performed after 25 subjects have been enrolled in this highest dosing arm. If at any point a risk-benefit balance in any cohort is found to be negative, then further enrollment will proceed at the lower dosing arm determined to be safe/tolerable based on the primary outcome and safety review with a 1:4 control:oxandrolone ratio and a total subject number of 100. If the second interim safety analysis leads to the conclusion that the lower dose (0.1 mg/kg oxandrolone BID) appears to be safe and well tolerated, while the higher dose (0.1 mg/kg oxandrolone TID) is not, then the enrollment will proceed in the 0.1 mg/kg BID arm with a 1:4 ratio. If the lowest dose of oxandrolone (0.1 mg/kg BID) is found to be unsafe, then the trial will be stopped. The benefit of this approach lies in the ability to allocate patients to the highest safe dose arm thus enriching the relevance of safety/tolerability and efficacy information obtained. A higher-dose treatment arm will be used if the data reveal the initial treatment arm is not different from control with regards to the primary outcome. If no safety/tolerability effect is demonstrated, the trial will, by design, function as a randomized, controlled trial with dose-escalation. It is anticipated that the study will conclude with approximately 80 oxandrolone patients (in up to three dosing arms) and 20 control patients.


Recruitment information / eligibility

Status Terminated
Enrollment 34
Est. completion date September 19, 2023
Est. primary completion date September 19, 2023
Accepts healthy volunteers No
Gender All
Age group N/A to 14 Days
Eligibility Inclusion Criteria: 1. HLHS and other single ventricle of right ventricular morphology 2. Age and Norwood procedure =14 days of age 3. Informed consent from parent/guardian Exclusion Criteria: 1. Small for gestational age (birth weight <10th percentile for gestational age) 2. Prematurity, defined as gestational age <37 weeks 3. Intrauterine growth retardation (birth weight =2.5 kg and gestational age =38 weeks) 4. Chromosomal abnormality, recognizable genetic syndrome or congenital anomalies of more than minor severity associated with growth failure 5. Moderate or greater right ventricular systolic dysfunction and/or moderate or greater tricuspid regurgitation prior to the Norwood procedure 6. Extracorporeal membrane oxygenation support (ECMO) prior to or within 24 hours of Norwood procedure 7. Pre-Norwood interventions (fetal intervention, balloon atrial septostomy for an intact or restrictive atrial septum) 8. Pre-Norwood pulmonary venous obstruction 9. Pre-Norwood procedure necrotizing enterocolitis and/or other gastrointestinal syndromes 10. Known contraindication to oxandrolone 11. Planned or current warfarin therapy at screening (warfarin effects are increased by anabolic drugs) 12. Significant hepatic dysfunction (elevation of serum transaminase levels greater than two times the upper limit of normal local laboratory standard at screening) 13. Hypercalcemia (>1.5 times upper normal range for lab) 14. Nephrotic syndrome 15. Unwillingness or inability to return to surgical center for follow-up evaluation 16. Participation in another clinical study that may impact growth

Study Design


Intervention

Drug:
Oxandrolone
Oxandrolone 2.5mg tabs will be suspended in multi-chain triglyceride (MCT) oil and administered buccally.

Locations

Country Name City State
Canada The Hospital for Sick Children Toronto Ontario
United States University of Michigan Health System, Ann Arbor Ann Arbor Michigan
United States Children's Hospital of Atlanta Atlanta Georgia
United States Boston Children's Hospital Boston Massachusetts
United States Medical University of South Carolina Charleston South Carolina
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Cook Children's Medical Center Fort Worth Texas
United States Texas Children's Hospital Houston Texas
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Primary Children's Medical Center Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
Carelon Research

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Biochemical evidence of hepatic dysfunction Elevation of serum transaminase levels (alanine transaminase (ALT) and/or aspartate transaminase (AST)) >4 times the local laboratory upper limit of normal From date of treatment initiation until the pre-SCPC evaluation or end of study participation, whichever comes first, up to 9 months
Primary Virilization Standardized physical examination will be performed. Because there are no standard normal values for the various measurements included, each subject will serve as their own control From date of treatment initiation until the completion of study drug therapy or end of study participation, whichever comes first, up to 28 days
Primary SAE probably or definitely related to oxandrolone therapy Any SAE probably or definitely related to oxandrolone therapy in the opinion of the medical monitor From date of treatment initiation until the pre-SCPC evaluation or end of study participation, whichever comes first, up to 9 months
Secondary Length-for-age z-score The efficacy of buccally administered oxandrolone will be evaluated by measuring length-for-age z-score at the end of study drug therapy At the time of completion of study drug therapy, up to 28 days after date of treatment initiation
Secondary Weight-for-age z-score The efficacy of buccally administered oxandrolone will be evaluated by measuring weight-for-age z-score at the end of study drug therapy At the time of completion of study drug therapy, up to 28 days after date of treatment initiation
Secondary Change in Weight-for-age z-score The efficacy of buccally administered oxandrolone will be evaluated by measuring the change in weight-for-age z-score at the end of study drug therapy From date of pre-Norwood procedure until completion of study drug therapy, up to 28 days
Secondary Change in length-for-age z-score The efficacy of buccally administered oxandrolone will be evaluated by measuring the change in length-for-age z-score at the end of study drug therapy From date of pre-Norwood procedure until completion of study drug therapy, up to 28 days
Secondary Prealbumin levels Serum prealbumin levels will be measured weekly During the duration of therapy
Secondary Lean Body Mass Lean body mass will be assessed using dual energy x-ray absorptiometry (DXA) At the completion of study drug therapy, assessed up to 35 days after initiation of study drug therapy
Secondary Decreased right ventricular systolic function Evidence of =moderate right ventricular systolic dysfunction or tricuspid valve regurgitation based on qualitative assessment of clinical echocardiograms if performed At the time of Norwood discharge and at the time of pre-SCPC evaluation, up to 9 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04992793 - Paediatric Brain Injury Following Cardiac Interventions
Recruiting NCT05213598 - Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
Completed NCT04136379 - Comparison of Home and Standard Clinic Monitoring of INR in Patients With CHD
Completed NCT04814888 - 3D Airway Model for Pediatric Patients
Recruiting NCT04920643 - High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery N/A
Completed NCT05934578 - Lymphatic Function in Patients With Fontan Circulation: Effect of Physical Training N/A
Recruiting NCT06041685 - Effect of Local Warming for Arterial Catheterization in Pediatric Anesthesia N/A
Recruiting NCT05902013 - Video Laryngoscopy Versus Direct Laryngoscopy for Nasotracheal Intubation N/A
Not yet recruiting NCT05687292 - Application of a Clinical Decision Support System to Reduce Mechanical Ventilation Duration After Cardiac Surgery
Not yet recruiting NCT05524324 - Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT N/A
Completed NCT02746029 - Cardiac Murmurs in Children: Predictive Value of Cardiac Markers
Completed NCT03119090 - Fontan Imaging Biomarkers (FIB) Study
Completed NCT02537392 - Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease N/A
Recruiting NCT02258724 - Swiss National Registry of Grown up Congenital Heart Disease Patients
Terminated NCT02046135 - Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery Phase 2
Completed NCT01966237 - Milrinone Pharmacokinetics and Acute Kidney Injury
Recruiting NCT01184404 - Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery N/A
Completed NCT01548950 - Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension N/A
Completed NCT01178710 - Effect of Simvastatin on Cardiac Function N/A